Headway2020 - A new roadmap in Mental Health
Brussels, October 9th, 2019: Angelini Pharma’s international Public Affairs initiative “Headway2020 : A new roadmap in Mental Health” goes public ahead of the 27th World Mental Health Day at the European Parliament.
Headway2020 is a European multidisciplinary platform launched in October 2017 by Angelini Pharma in partnership with The European House – Ambrosetti, aimed at stimulating the debate and at setting new priorities in the management of patients suffering mental health disorders.
The main goal of the initiative is to generate thorough proposals and actionable solutions to best improve both management and care of patients affected by mental disorders, drafting and then implementing specific action plans in three EU Member States – i.e. Italy, Spain and Poland.
Numerous key professionals and stakeholders with diverse background from the above mentioned three countries did enthusiastically join the project. They all committed to National Working Groups operating in Italy, Spain and Poland, and shared experiences and best practices during an International Workshop that took place in October 2018 in Rome under the patronage of the Italian Ministry of Health. As a matter of fact, each National Working Group produced recommendations and guidelines, most of which have already been forwarded to policy-makers and are currently informing decision-making processes.
On October 9th, 2019, Headway2020 3-year journey came to conclusion with a high-level Forum hosted by the EU Parliament. Among others, MEPs, European multidisciplinary experts and academics, health economists and patients’ associations representatives joined the event to discuss and share experiences and final recommendations.
As it regards Angelini, Headway2020 is a clear testimony of Angelini’s commitment to Mental Health and is a proof of the Company’s growing leadership in the neurosciences field.
Angelini Pharma strongly believes supporting such initiatives in the policy-making space, and recognizes the value of going “beyond the pill” with its unwavering commitment to patients and their families.